Protecting patient privacy when sharing patient-level data from clinical trials by Katherine Tucker et al.
CORRESPONDENCE ARTICLE Open Access
Protecting patient privacy when sharing
patient-level data from clinical trials
Katherine Tucker1*, Janice Branson2, Maria Dilleen3, Sally Hollis4,5, Paul Loughlin4, Mark J. Nixon6 and Zoë Williams7
Abstract
Background: Greater transparency and, in particular, sharing of patient-level data for further scientific research is an
increasingly important topic for the pharmaceutical industry and other organisations who sponsor and conduct
clinical trials as well as generally in the interests of patients participating in studies. A concern remains, however,
over how to appropriately prepare and share clinical trial data with third party researchers, whilst maintaining
patient confidentiality. Clinical trial datasets contain very detailed information on each participant. Risk to patient
privacy can be mitigated by data reduction techniques. However, retention of data utility is important in order to
allow meaningful scientific research. In addition, for clinical trial data, an excessive application of such techniques
may pose a public health risk if misleading results are produced. After considering existing guidance, this article
makes recommendations with the aim of promoting an approach that balances data utility and privacy risk and is
applicable across clinical trial data holders.
Discussion: Our key recommendations are as follows:
1. Data anonymisation/de-identification: Data holders are responsible for generating de-identified datasets which
are intended to offer increased protection for patient privacy through masking or generalisation of direct and
some indirect identifiers.
2. Controlled access to data, including use of a data sharing agreement: A legally binding data sharing
agreement should be in place, including agreements not to download or further share data and not to attempt
to seek to identify patients. Appropriate levels of security should be used for transferring data or providing
access; one solution is use of a secure ‘locked box’ system which provides additional safeguards.
Summary: This article provides recommendations on best practices to de-identify/anonymise clinical trial data for
sharing with third-party researchers, as well as controlled access to data and data sharing agreements. The
recommendations are applicable to all clinical trial data holders. Further work will be needed to identify and
evaluate competing possibilities as regulations, attitudes to risk and technologies evolve.
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Background
Introduction
This article is one of a series of articles developed by
the EFSPI (European Federation of Statisticians in the
Pharmaceutical Industry) [1] and PSI (Statisticians in
the Pharmaceutical Industry) [2] Data Sharing Work-
ing Group. The working group consists of medical re-
search statisticians from both pharmaceutical industry
and academia with the intention of providing know-
ledge and insights regarding the practical challenges
and opportunities of accessing clinical trial data for
re-analysis or secondary scientific research purposes.
The intended audience for this article comprises of any
holder of patient-level data generated from clinical trials
(referred to as ‘data holder’), who wishes to share data for
the purpose of secondary scientific research. It will also be
useful background information for academic researchers
who aim to access patient level data from clinical trials, in
understanding what steps may have been applied to the
data in order to protect patient privacy.
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Greater transparency and, in particular, sharing of
patient-level data for further research is an increasingly im-
portant topic for the pharmaceutical industry and other or-
ganisations who sponsor and conduct clinical trials
(government agencies, academia, charities etc.). Drivers of
these changes have come from several sources - for ex-
ample, the scientific community/academia, e.g. Alltrials [3],
BMJ (British Medical Journal) Open Data Campaign [4];
regulators, e.g. EMA (European Medicines Agency) policy
0070 [5] and the pharmaceutical industry e.g. PhRMA/
EFPIA principles (Pharmaceutical Research and Manufac-
turers of America, European Federation of Pharmaceutical
Industries and Associations) [6].
This paradigm shift aims to maximise the value of
patient-level data from clinical trials for the benefit of
future patients and society, by sharing clinical trial data
with researchers for secondary research. At the same
time it is also essential that this is balanced with the risk
to the privacy and identity of individual patients. Thus a
process step to protect patient data privacy is an essen-
tial prerequisite for data sharing in order to adequately
safeguard the privacy of patients participating in clinical
trials, whilst making data available for further research.
The article briefly considers existing legislation, guid-
ance and common practices and then recommends best
practices relevant to protecting patient privacy, when
sharing clinical trial data. Our recommendations aim for
an approach that balances data utility and privacy risk
and is applicable to any holder of clinical trial data.
Scope and assumptions
The following topics related to protecting patient priv-
acy, when sharing patient-level data from clinical trials,
are in-scope for this article:
 best practices for data anonymisation/de-
identification
 the role of controlled access (e.g. via a secure ‘locked
box’ system)
 legally binding data sharing agreements (DSAs)
It is important to recognise that the level of data de-
identification required will relate to the level of security and
safeguards in the method of sharing. For example, making
data available on the internet, with no legal agreements in
place, greatly increases the number of people with access to
the data. Those accessing data may have a variety of mo-
tives for doing so, potentially including attempting to reveal
patient identities, with no legal agreement to prevent this
or control on access. Therefore, in this scenario, data must
be prepared such that the risk of an ‘attacker’ being able to
reveal patient identities is minimal (i.e. high levels of data
anonymisation/de-identification). We do not consider this
scenario further within this article.
The recommendations in this article assume the data
are being shared in the context of genuine scientific re-
search, based on agreed research objectives, with some
minimum level of legal, data security and access safe-
guards being employed. In this scenario, the overall risk of
a researcher being motivated to reveal patient identities is
expected to be very low, and potentially any breach of
privacy would have serious professional consequences.
Therefore data can be prepared in such a way that greater
utility is retained in order to enhance the integrity of
resulting analyses and interpretation. However, the data
holder is ultimately responsible for ethical and legal obli-
gations and assessing risk of patient re-identification
(based on level of security, safeguards, etc.).
The following are out of scope for this article, but will
also be important considerations for data holders when
sharing clinical trial data:
 broader aspects related to patient privacy when
sharing clinical trial data, including informed
consent, the criteria determining which studies are
available for sharing, request tools and processes,
statistical analysis software or tools provided, and
legal aspects of DSAs. The PhRMA/EFPIA
‘Principles for Responsible Clinical Trial Sharing’ [6]
and the Institute of Medicine report ‘Sharing
Clinical Trial Data: Maximizing Benefits,
Minimizing Risk’ [7] address several of these aspects.
The companion EFSPI/PSI Working Group article
Data Sharing: Accessing and Working with
Pharmaceutical Clinical Trial Patient Level Datasets
– a Primer for Academic Researchers (EFSPI/PSI
Working Group on Data Sharing:Accessing and
Working with Pharmaceutical Clinical Trial Patient
Level Datasets – a Primer for Academic
Researchers. In submission), provides an overview of
topics such as finding information, writing a
research proposal, the review process, how data are
shared and expectations of the data holder.
 appropriate standards for security when sharing
data.
 redaction and sharing of documents e.g. clinical
study reports (CSRs) including consideration of
‘commercially confidential information’ which is
discussed in more detail in TransCelerate [8] and
EMA guidance [5, 9].
Terminology and definitions
For the purposes of this article, we have used the follow-
ing definitions:
Patient-level data
EMA policy 0070 [5] defines Individual Patient Data as
“the individual data separately recorded for each
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participant in a clinical study”; for the purposes of this
article we call this ‘patient-level data’. Examples of
patient-level data collected in clinical trials are patient
identifier, site identifier, date of birth, gender, race, effi-
cacy outcomes, laboratory test results, etc.
Anonymised/de-identified data
Guidance on implementation of the EMA policy 0070 [9]
defines anonymisation as “the process of rendering data
into a form which does not identify individuals and where
identification is not likely to take place”, and anonymised/
de-identified data as “data in a form that does not identify
individuals and where identification through its combin-
ation with other data is not likely to take place”.
The Health Insurance Portability and Accountability
Act (HIPAA) [10] defines “de-identified protected health
information’ as ‘Health information that does not identify
an individual….there is no reasonable basis to believe
that the information can be used to identify an
individual….”.
Note that terms ‘de-identification’ and ‘anonymisation’
are often used interchangeably in different contexts in
the literature.
Raw and derived data
Raw data means patient-level data that have been directly
collected during a clinical trial or study (e.g. weight and
height of a patient). Derived data are data that is obtained
from raw data and which have undergone a derivation or
calculation (e.g. body mass index is derived from the
weight and height of a patient). Patient-level data to be
shared can include raw and/or derived data.
Data holder
Entity which holds the clinical trial data and has the ability
and authority to share with third party researchers.
Existing legislation, guidance and common practices
This section briefly outlines existing legislation, guidance
and common practices.
There are various elements of EU (European Union) le-
gislation and EMA (European Medicines Agency) policy
which relate to data transparency [5, 11–13]. EU data priv-
acy legislation [12, 13] states that “The principles of (data)
protection should not apply to data rendered anonymous
in such a way that the data subject is no longer identifi-
able.” In December 2015, the EU governmental institu-
tions reached agreement on the text of the new General
Data Protection Regulation that will replace the existing
Directive [14]. This new Regulation was adopted by the
EU Parliament and Council in May 2016 and will be be-
come applicable in 2018. The precise impact of this new
Regulation on matters discussed in this paper is still not
totally clear but will emerge during the two year transition
phase. Whilst EMA focus is currently on greater transpar-
ency of documents, EMA policy 0070 [5] does include po-
tential future provision for sharing of patient-level data. It
includes reference to EU article 29 WP216 [15], which is
critiqued by Khaled El Aman [16], and the EMA’s guid-
ance on implementation [9] addresses anonymisation of
personal data of trial participants which will be relevant to
the sharing of patient-level data.
US Policy 45 CFR part 46, also known as the ‘Com-
mon Rule’ [17], requires de-identification of data prior
to release for further research. US ‘HIPAA’ privacy
rule [10] outlines two approaches commonly applie-
d:’Expert Determination’ and ‘Safe Harbor’. The’Expert
Determination’ approach requires a statistical expert
to apply statistical and scientific principles in order to
render data not individually identifiable or such that
the risk of re-identification is very small. The ‘Safe
Harbor’ approach requires removal of eighteen direct
identifiers which could be used to identify the individ-
ual or the individual’s relatives, employers, or house-
hold members, many of which are not routinely
collected in clinical trials and applies to US
Table 1 HIPAA eighteen direct identifiers
A. Name
B. Geographic subdivisions smaller than a state. The initial three digits of
a ZIP code can be retained if certain criteria are met.
C. With the exception of year, all elements of dates directly related to an
individual (such as birth date, admission date, discharge date, date of
death). For ages over 89 and elements of dates (including year)
indicating such an age, ages and elements may be aggregated into a




G. Social security numbers
H. Medical record numbers
I. Health plan beneficiary numbers
J. Account numbers
K. Certificate/licence numbers
L. Vehicle identifiers and serial numbers,
including license plate numbers
M. Device identifiers and serial numbers
N. Web Universal Resource Locators (URLs)
O. Internet Protocol (IP) addresses
P. Biometric identifiers, including finger and voice prints
Q. Full-face photographs and any comparable images
R. Any other unique identifying number, characteristic, or code, except
as permitted by paragraph (c) of HIPAA Safe Harbor section; and
S. The covered entity does not have actual knowledge that the
information could be used alone or in combination with other
information to identify an individual who is a subject of the
information
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populations. The eighteen ‘Safe Harbor’ direct identi-
fiers are outlined in Table 1. Building on the principles
outlined in HIPAA, Hrynaszkiewicz [18] considers
both direct and indirect identifiers, with a focus on
publication of data for unrestricted access.
The Institute of Medicine report ‘Sharing Clinical Trial
Data: Maximizing Benefits, Minimizing Risk’ [7] includes
an appendix ‘Concepts and Methods for De-identifying
Clinical Trial Data’, which focuses on quantifying risk of
re-identification. Mello [19] and the IPPC (International
Pharmaceutical Privacy Consortium) report [20] also
consider the de-identification of clinical trial data, whilst
NIH (National Institute of Health) requires its investiga-
tors to deliver data sets prepared in order to reduce the
risk of re-identification [21].
Various approaches to transforming data to preserve
privacy of the subjects have been proposed across a
broad range of data sharing situations. Aggarwal and Yu
[22] and the Institute of Medicine [7] provide examples
of approaches to achieve anonymity of personal health
information, including the following:
 Transformation of data sets using data reduction
techniques such as generalisation of the data by
grouping of values into categories, and suppression/
masking of data where specific values or whole
records are removed from the dataset. Data
perturbation techniques can also be applied,
whereby random noise is added to the true values.
 Diversity/closeness models have been developed
with the aim of transforming data to ensure that
specific individuals cannot be identified within
public databases [23]. These provide a guarantee of a
pre-specified level of anonymity based on non-
uniqueness of records within the transformed data.
 Provision of aggregate results, such as area level
census data.
 Provision of the results of data analysis such as data
mining through applications which hide certain data
attributes rather than direct access to data.
There are a variety of existing models for requesting
access to pharmaceutical clinical trial data; some examples
include ClinicalStudyDataRequest.com [24], ‘YODA’ (Yale
University Open Data Access) [25], Pfizer [26]. On these
websites, companies outline their procedures for de-
identifiying/anonymising clinical trial data (see example
outlining GSK (GlaxoSmithKline) principles [27], also
adopted by some other data holders with some variations).
These examples are broadly representative of the steps im-
plemented by many pharmaceutical companies. Guidance
aimed at UK publically funded clinical trials units has
been published, funded by the UK MRC Network of Hubs
for Trials Methodology Research [28]. ‘The 5 Safes’ [29]
outlined by the UK Data Service, holistically considers
‘Safe People’, ‘Safe Projects’, ‘Safe Settings’, ‘Safe Outputs’
and ‘Safe Data’, when sharing sensitive data for research.
TransCelerate [30] and PhUSE (Pharmaceutical Users
Software Exchange) [31] are pharmaceutical industry bod-
ies with working groups who have recently developed
models or standards around data de-identification. Whilst
TransCelerate is focusing on general principles, PhUSE fo-
cuses on specific implementation rules in CDISC SDTM
3.2 (Clinical Data Interchange Standards Consortium,
Study Data Tabulation Model) and provides guidance on
determining which data elements may be direct or indir-
ect identifiers. Whilst these guidances focus primarily on
pharmaceutical clinical trial data, the general principles
could be more generally applied.
Discussion
This section outlines key recommendations in two areas:
anonymisation/de-identification of patient-level data for
third-party research and controlled access to data, in-
cluding use of a DSA.
Data anonymisation/de-identification
To create these recommendations for best practices for
anonymisation/de-identification of patient-level clinical
trial data, we have considered:
 relevant legislation, guidance and common practices,
 context in which data holders share data (e.g.
approved research proposals, legal and data security
controls),
 practical considerations related to the ability to
efficiently and effectively prepare and deliver large
volumes of data requests in a semi-automated
fashion,
 ability to align/standardise processes across data
holders,
 cost and resource implications,
 how to retain data utility.
Patient confidentiality can never be 100 % guaranteed,
especially as the general availability of data in the public
domain increases over time, including social media. If
these external data were to be combined with the de-
identified clinical trial data provided, it may increase the
risk of patient re-identification. Data holders take the
protection of patient privacy seriously. Whilst no data
holder can completely rule out illegitimate attempts to
re-identify data, they can employ a number of strategies
to minimise the risk and this article highlights those we
consider as best practice.
This guidance aims to provide pragmatic and effective
recommendations in order to minimise breaches of pa-
tient confidentiality (e.g. revealing of the true identity of a
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patient), whilst maximising data utility (e.g. ability of a re-
searcher to conduct meaningful analyses). Applying high
levels of data de-identification may result in data that is
not useful for answering scientific questions, or results in
misleading interpretation. Conversely, provision of useful
data with lower levels of de-identification, may raise the
risks around patient confidentiality. This article attempts
to strike a pragmatic balance between the two.
In making our recommendations, we assume the
following:
 The process for receiving, reviewing and approving
any required research proposal has been completed.
Data will only be shared in relation to ‘approved’
research proposals with named researchers, only
whom will have access to the data.
 Data will be shared in a secure and controlled
manner under a DSA with legal safeguards on
misuse of data (see later section).
 Both raw and analysis-ready datasets may be pro-
vided to researchers and the recommendations apply
to both types of data. However, genetic data are out
of scope for this article as we consider that the po-
tential for sensitive information to be released (e.g.
previously unknown genetic abnormalities which
may have serious implications on that person’s fu-
ture health) and the risk of patient re- identification
to be too high (as the set of genetic results will al-
ways be unique to each patient).
Clinical trials often involve collection of data from pa-
tients across geographical boundaries. Researchers will
also reside across the globe. As such, data anonymisa-
tion/de-identification rules need to be applicable to data
collected in any country and also potentially shared with
researchers residing across the world.
The HIPAA Privacy Rule [10] outlines two approaches to
de-identification of data,’Expert Determination’ and ‘Safe
Harbor’. It is recognised that there are particular difficulties
in applying’Expert Determination’ algorithms to high-
dimensional data. Eze and Peyton [32] note that most
diversity/closeness models fail with high-dimensional health
data because the non-uniqueness that is required “results in
excessive information loss, virtually wiping off the analytical
utility of the dataset”. This is a particular issue for clinical
trial data due to the nature of the high-dimensionality, and
because some types of data are critical for data utility but not
amenable to a non-uniqueness approach. Compared to rou-
tinely collected health data, the ratio of the number of data
fields to the number of subjects will be considerably higher
creating a more extreme challenge. Some critical information
such as rare adverse events have an inherently high level of
uniqueness, and we consider that the use diversity/closeness
models would generalise the data unacceptably.
Thus our recommendation is to utilise a de-
identification approach in line with HIPAA ‘Safe Harbor’,
with further generalisation and masking of some indirect
identifiers. Whilst initially written with the US popula-
tion in mind, this approach lends itself to some level of
automation and consistent approach across studies. This
can potentially enable quicker processing and delivery of
large volumes of studies and datasets and therefore pro-
vides a good starting point for our recommendations. It
also better enables subsequent pooling/meta- analyses as
all de-identified/anonymised studies can be handled uni-
formly, whereas expert determination may result in dif-
fering levels of de-identification/anonymisation, for
example based on differing patient populations.
Whilst our aim in this article is to recommend steps
which can be automated to some extent, it is important
that data holders do not consider the process as purely a
‘push button’ exercise. Preparing data for sharing will al-
ways involve some element of manual review in order to
identify and remove unexpected identifiers in the data,
particularly for legacy data which maybe have less stand-
ardisation. In addition, data holders should review their
data anonymisation/de-identification steps regularly to
ensure they remain in line with current thinking and
guidance.
The specific quantification of risk (of patient re-
identification), the acceptable risk threshold and the
methods employed to do so are the responsibility of the
data holder.
Recommended best practices
We consider the following as best practices for anonymi-
sation/de-identification, however the specific steps taken
will depend on the individual circumstances of the re-
quest, how the data will be shared and other trial-related
information.
 Direct identifiers: Any of the HIPAA direct
identifiers collected in clinical trial data should be
removed. Dates are handled as described below. The
eighteen direct identifiers are outlined in Table 1.
 Patient identifiers: In clinical trials, each patient is
given a unique number or code (patient code
number/identifier) and these are classed as direct
identifiers. They are generally used across datasets.
To maintain the link across records between
datasets, patient identifier codes should be replaced
with new randomly generated numbers/identifiers
consistently across datasets and extension studies
(where applicable). The new patient identifier should
not depend at all on information contained in the
corresponding records. This ensures there is no
identifier present in the data which directly links to
the original patient-level data and patient notes
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which, for example, would be present at the clinical
trial site, together with other direct identifiers such
as name and address.
 Code key: The data holder should ensure that the
‘code key’ that was used to generate the new code
number from the original is securely stored, or
destroyed. As noted by the Institute of Medicine,
the data holder will, by definition, be able to re-
identify the data as they retain the original trial data.
Thus the minimum standards of security if the ‘code
key’ is retained are those applied to the original data
such as storage in a secure location with access by
only limited and authorised personnel.
 Dates: Date of birth is information that might lead to
identification of a specific patient and therefore it
should be replaced with age. Other patient related
dates, including date of death, should be replaced by
study day relative to a reference date or by offset dates
(the offset approach is described further in
TransCelerate report ‘Data De-identification and
Anonymization of Individual Patient Data in Clinical
Studies – A Model Approach’ [30] and PhUSE De-
identification Standard for SDTM 3.2 [31]). The
PhUSE standard also contains commentary compar-
ing study day versus offset methods, and describes
some of the issues with offset dates. EMA guidance
on implementation of their policy on publishing clin-
ical trial data suggests that the offset dates should be
within the range of dates occurring during the trial,
which may require complex algorithms in some cases
such as variable duration of follow-up. Currently, the
use of one method over another is based on data
holder preference. The PhUSE standard states that it
is preferable, from a data utility perspective, to keep
both actual dates with offsets applied and relative
study day. Further work is required to assess the im-
plications of different approaches to generating offsets
and their implications for data utility and the risk of
re-identification. Study day retains much of the scien-
tific value in the date information, while avoiding the
uncertain risk that may arise from the use of offsets.
Since removal of information relating to actual dates
may significantly reduce data utility in seasonal type
diseases such as influenza or hayfever, alternative
Table 2 Specific recommendations for indirect identifiers
Site Code Number/Investigator Identifier
• In clinical trial data, place of treatment is usually collected as a site code number/investigator identifier. These site codes should be re-coded to a new
random site code (similar to patient code number/identifier). Sites which include few patients may be aggregated to a single site code number/identi-
fier. Countries which include few patients could also be pooled.
Demographics and anthropometry measures
• Date of birth is a direct identifier and should be should be replaced with age. As a general rule, ages above 89 should be set to a category ‘ > 89’;
however depending on the disease and the population under consideration, further grouping of age categories should be considered.
Consideration should also be given to recoding/grouping other ages at the lower or upper limits. Another consideration, assuming this does not
impact data utility adversely, is to group ages (for example into five year age categories). All other patient-related dates including date of death
should be removed and replaced either with a derived study day relative to a baseline or reference date or offset by some random interval.
• Gender can be kept and it is recommended that race is mapped into categories (e.g. FDA recommendations: American Indian or Alaska Native,
Asian, Black or African American, Native Hawaiian or Other Pacific Islander, and White). Ethnicity is usually removed.
• Anthropometry measures (e.g. weight, height) should be kept in de-identified datasets as they are frequently key variables for dosing (e.g. mg/kg)
or present in the calculations of body surface area (BSA) or body mass index (BMI) or used as covariates in data analyses. Consider grouping
variables.
Verbatim text
• Verbatim (free) text may include information that identifies a patient e.g. names, dates or other personal information. Examples of variables
containing verbatim text are adverse events, medications, medical history and general comments. Preferably, variables containing free text are either
removed from the dataset or set to blank. Alternatively, the data could be reviewed to assess the risk of patient identification, especially if the data
add scientific value to the dataset, and any identifiers at the observational level removed.
• Where a variable has been coded according to a standard dictionary (e.g. adverse events to MedDRA, medications to WHO ATC), the dictionary
term(s) should be retained in the dataset and the verbatim text dropped.
Small populations, low frequency and rare events, rare diseases, sensitive data
• Hrynaszkiewicz recommends that for indirect identifiers with small denominators (population size of <100) or very small numerators (event counts
of <3), may present a risk if present in combination with other indirect identifiers. However, to exclude such data in all cases may limit the ability
of a researcher to perform meaningful analyses, particularly in the case of small numerators for adverse event reporting which may result in the
removal of rare events of interest.
• Studies involving rare diseases or including sensitive data should be reviewed on a case by case basis and assessed as to whether sufficient steps
can be taken to adequately maintain patient confidentiality.
Other
• Potential indirect identifiers which are important for data utility may be retained and could be recoded/grouped, otherwise they should be
removed.
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approaches may need to be considered in these sce-
narios e.g. the data holder may derive and retain
month or season information.
 Indirect identifiers: Specific recommendations for
indirect identifiers can be found in Table 2. Potential
indirect identifiers which are important for data
utility may be retained and could be recoded/
grouped, otherwise they should be removed.
Process, quality control and documentation
It is important the data holders define a process for data
anonymisation/de-identification, execute that process
and then have a separate quality control step to review
and document correct implementation of the process.
During this process of preparation of the data, program-
mers will need to refer to both original and new datasets
and once completed, the ‘code key’ linking both sets of
data is deleted or secured. This step may also include as-
sessment of risk of patient re-identification.
Ideally, we recommend that to reduce the risk of re-
identification, data holders only provide a subset of the data
as required to fulfil the research proposal. However, for effi-
ciency reasons, data holders may wish to provide all data-
sets for a study. Whilst providing the full set of data may
increase risk of re-identification, it also ensures that the re-
searcher can draw on any data that are relevant to their in-
terpretations, even if they had not anticipated the specific
need for that data. Even if a subset of the data are shared, it
may be more efficient to de-identify/anonymise an entire
study at once, so it is ready for future requests, particularly
in circumstances where the data holder chooses to destroy
the linking code key.
Supporting documentation such as redacted versions
of the Clinical Study Report (CSR), protocol, statistical
analysis plan, dataset specifications, annotated CRFs
(case report form) and in certain cases statistical pro-
grams (or sections of ‘pseudo’ code which outlines key
derivations or statistical models fitted) should be pro-
vided to researchers, where available, in order to help re-
searchers navigate and understand the datasets.
In addition, documentation should be provided outlin-
ing steps taken to de-identify/anonymise the data and
further details if only a subset of the data is provided.
For example, a report might outline the variables re-
moved or aggregated for each dataset with details of
how variables had been altered (e.g. age replaced by age
categories). This is important given that the original
dataset specifications will not exactly match the newly
de-identified/anonymised data provided. Documents e.g.
the main text of CSRs should be redacted at least to the
same extent as patient-level data (e.g. all patient identi-
fiers to be removed) and patient level listings and tabula-
tions should be completely removed. Further guidance
on redaction of CSRs is available [8, 9].
Controlled access to data, including use of a data sharing
agreement (DSA)
This section outlines our recommendations for providing
the researcher controlled access to clinical trial data, includ-
ing use of DSAs. In order to protect patient privacy, access
to data should be provided following these minimum
recommendations:
1. A DSA (also sometimes known as data use
agreement or DUA) should be signed by data holder
and researchers, which includes sufficient limitations
on what the recipients can and cannot do with the
data. This should relate to a specific research
proposal which has already been agreed and
approved.
2. Only named (and appropriately qualified)
researchers should be granted access to the data.
3. Appropriate levels of security should be used when
transferring data or providing access to data.
Whilst a secure ‘locked box’ system (e.g. SAS Clinical
Trial Data Transparency (CTDT) Multi Sponsor Environ-
ment (MSE)) [33] is not a necessity, it does provide add-
itional safeguards to maintain patient privacy, as well as
other features such as provision of analytical software and
ability to simultaneously share data from multiple data
holders with researchers. Features may include secure
transfer of data and documents, ability to grant and revoke
access to specific researchers (i.e. secure password pro-
tected login), ability to restrict downloading and cut and
pasting of patient-level data to researchers’ personal com-
puter, an audit trail accessible by the data holder etc. If a se-
cure ‘locked box’ system is not utilised, then additional
conditions to incorporate into the DSA, are outlined below.
A legally binding DSA should include at a minimum:
 Agreement to only use the data for the agreed
purpose (based on an approved research proposal)
and not to download, transfer or share the data for
future use with anyone else
 Under no circumstances to attempt to seek to
identify patients
 Individual passwords only to be used by assigned
individuals to restrict access to data and in the case
of secure transfer not to share with others
 If a secure system is not used, then additional
conditions may be required such as:
○ researchers must agree to assume responsibility
for securely storing and managing access to
data and documents;
○ the DSA may be extended to name all
individuals who will access the data (in secure
systems, this may be manageable via system
controls);
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○ researchers to prevent dissemination of
datasets to individuals who are not identified in
the DSA;
○ appropriate management of data and
documents once all research is complete (i.e.
destruction/deletion from systems)
 In addition to concerns regarding patient privacy,
consideration should be given to the process for
handling potential new safety signals if identified
(e.g. to inform the data holder immediately),
researchers providing the data holder with a copy of
the subsequent publication (for information and/or
review) and citation, agreements regarding any
inventions arising from the research and
acknowledgements referring to provision of the data
by the data holder.
Future considerations
One overarching aim for the future is to maximise the
ability of researchers to access consistently structured
and prepared data from multiple sources, including
pharmaceutical and non-commercial trial data (e.g. aca-
demia, government bodies, and charities). Therefore,
EFSPI/PSI fully supports efforts to align processes, tools
and systems across data holders with an aim for eventual
alignment around a central repository, thereby allowing
further sharing of experiences and costs and improving
the experience and accessibility for researchers.
A topic which will continue to evolve is the extent to
which data holders quantify risk of patient re-
identification through the use of data sources and data
linkage techniques that are available now, or those that
may become available in the future. For data that are be-
ing shared publically, this could include the risk of a de-
liberate attack using data from public records and social
media could leading re-identification. However, as dis-
cussed above, this scenario is considerably less likely
when data sharing through controlled access by qualified
researchers for an agreed purpose. As methods develop
further, it may be possible for risk quantification to move
from a qualitative to a quantitative assessment for clin-
ical trial data de-identification. Indeed, clinical trials
should be planned and executed with eventual data shar-
ing aims built in, in line with the Institute of Medicine
[7] recommendation that ‘Stakeholders in clinical trials
should foster a culture in which data sharing is the ex-
pected norm’, and the International Committee of Med-
ical Journal Editors (ICMJE) proposal to require authors
to share with others de-identified individual-patient data
underlying the results presented in articles reporting
clinical trials [34].
Regulatory guidance and legalisation is an evolving
area which may eventually mandate minimum steps for
data de-identification and anonymisation to facilitate
patient-level data sharing. EFSPI/PSI are keen to partici-
pate and contribute to any future consultation with
EMA on the provision of patient-level data.
It is recognised that the resources, costs and effort re-
quired to make patient-level data available for third
party research may be considerable, particularly during
the early days of implementation of processes and prac-
tices. The burden on smaller data holders will be pro-
portionately greater than larger companies or groups
with more resources at their disposal. However, as out-
lined in this article, regulations may eventually mandate
sharing of patient-level data from pharmaceutical com-
panies and so starting this debate and sharing recom-
mendations now may allow data holders to be in a good
position to be able to address future regulatory needs.
Increasing standardisation of data collection, tabula-
tion and reporting, at least in the pharmaceutical indus-
try, should consequently mean data de-identification and
anonymisation steps can also be further automated,
thereby eventually reducing costs in preparing data for
sharing. An increasing number of contract research or-
ganisations are also offering services and tools to de-
identify and anonymise data as well as perform quantita-
tive risk assessments when required.
Summary
This article outlines best practices for data anonymisa-
tion/de-identification and controlled access to data in-
cluding the use of DSAs, in order to protect patient
privacy when sharing clinical trial data with third-party
researchers. The guidance is applicable to any holder of
clinical trial data, with the aim of promoting an ap-
proach that balances data utility and privacy risk and is
applicable across data holders.
In creating these recommendations, we considered
existing legislation, guidance and common practices rele-
vant to protecting patient privacy; the context in which
data holders share data (e.g. approved research proposals,
legal and data security controls); practical considerations
related to the ability to efficiently and effectively prepare
and deliver large volumes of data requests in a semi-
automated fashion; ability to align/standardise processes
across data holders; cost and resource implications, and fi-
nally how to maximise data utility and hence the integrity
of resulting analyses and interpretation.
Our key recommendations are:
1. Data holders are responsible for generating de-
identified and anonymised datasets which protect
patient privacy. Direct and some indirect identifiers
must be removed from datasets. This includes re-
coding patient identifier codes (by replacing the ori-
ginal code number with a new code number),
removing free text verbatim terms, replacing date of
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birth with age (and possibly grouping) and replacing
all patient related dates with study day or offset
dates. Potential indirect identifiers which are import-
ant for data utility may be retained and could be
recoded/grouped, otherwise they should be
removed.
2. A legally binding data sharing agreement should be
in place, including agreements not to download or
further share data and not to attempt to seek to
identify patients. Access to data should be
transferred and provided in a secure manner (data
holders should password protect data at a
minimum); one solution is use of a secure ‘locked
box’ system which provides additional safeguards.
We consider that these pragmatic recommendations
strike a reasonable balance between maintaining patient
privacy and retaining data utility, in order for the data to
be as valuable as possible for further secondary research,
the ultimate objective of data sharing. Further work will
be needed to identify and evaluate competing possibil-
ities as regulations, attitudes to risk, and technologies
evolve.
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